Study hints at new pathway for MRSA vaccine

New pathway for MRSA vaccine
New pathway for MRSA vaccine | Courtesy of medicalexpo.com

NYU Langone Medical Center announced Wednesday that its research recently found a possible new pathway to developing a vaccine for Staphylococcus aureus, commonly called HA-MRSA.

According to the Centers for Disease Control and Prevention (CDC), 10,000 people die each year from HA-MRSA; most of these people are hospital patients.

Researchers conducted a series of experiments in human and mice immune cells. They discovered that whether or not there were bacterial poisons, or dueling toxins, present made a main difference between HA-MRSA and community-acquired Mrsa (CA-MRSA), which is the less virulent, more common, community-based strain of MRSA’s main infection. The discovery shows why a specific HA-MRSA strain has grown more deadly than other strains of the virus.

"Essentially, in community-acquired MRSA, the toxins neutralize each other, while in the hospital superbug form, they do not,"  NYU Langone Microbiologist Victor Torres, the study's senior investigator, said.

This discovery opens new opportunities for scientists to create vaccines for these illnesses.

"No longer can we take an isolated approach of trying to target and block one leukotoxin at a time," Torres said. "We have to take a broader view of the pathogen and will likely have to target more than one toxin in order to develop an effective vaccine,"

Further details are available in the Nature Communications journal available online.

Organizations in this Story

NYU Langone Medical Center

Want to get notified whenever we write about NYU Langone Medical Center ?
Next time we write about NYU Langone Medical Center, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.